$CRVS News

Corvus Pharma Q2 2026 Earnings Call Transcript

Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa

Corvus Pharmaceuticals Starts Enrollment In Its Phase 1b Clinical Study Of Soquelitinib To Treat Hidradenitis Suppurativa

Corvus Pharmaceuticals (CRVS) Faces A Valuation Test, Is The Upside Already Priced In?

Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference

Corvus Pharmaceuticals: Steady As She Goes With Strong Footing In Atopic Dermatitis Treatment

Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial

Corvus Pharmaceuticals (CRVS): This Clinical-Stage Drugmaker Just Got A Lot More Interesting

Corvus Pharmaceuticals (CRVS) Q2 2026 Earnings Call Transcript

Corvus: Evaluating Soquelitinib's Science, Market Reach, And Fair Value

Corvus: Strong Buy Soquelitinib Q1 2027 Interim Futility Analysis And AD Drug Advancement

Corvus Pharmaceuticals Inc (CRVS) (Q2 2026) Earnings Call Highlights: Advancing Soquelitinib ...

Corvus Pharmaceuticals, Inc. (CRVS) Q2 2026 Earnings Call Transcript

Corvus Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary

Corvus Pharmaceuticals Q2 Earnings Call Highlights

Corvus Pharmaceuticals (NASDAQ:CRVS) Misses Q2 Loss Estimates as Clinical-Stage Spending Continues

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results

Corvus Pharma Q2 EPS $(0.19) Misses $(0.17) Estimate

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026

Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?